BGI Purchases 128 Illumina HiSeq™ 2000 Sequencing Systems
News Jan 13, 2010
Illumina, Inc. has announced that the BGI (formerly known as the Beijing Genomics Institute) has purchased 128 HiSeq 2000 sequencing systems, representing the largest single order for next-generation sequencing systems to date. Most of the units will be installed in BGI’s new genome center in Hong Kong.
“BGI’s investment in Illumina’s new HiSeq 2000 system is an important step in our effort to develop a premier sequencing facility that serves scientists globally.”
“BGI’s investment in Illumina’s new HiSeq 2000 system is an important step in our effort to develop a premier sequencing facility that serves scientists globally,” said Xiuqing Zhang, vice president of BGI. “Our goal is to build partnerships and collaborations around the world that contribute to the overall improvement of our global society. Creating solutions that enhance agriculture and food production, for example, are a key focus for us, as well as more region-specific programs, such as the development of the personal genomics field in China.”
BGI is among the scientific organizations committed to understanding biology and medicine through the use of large-scale sequencing and bioinformatics analysis. BGI has research centers in the United States, Europe, and Hong Kong, and seven genome research centers in mainland China for scientific collaboration and sequencing services.
Last month, BGI signed a long-term agreement with China Development Bank. The initial funding (1.5 billion US$) will help BGI build research and application platforms for sustainable development in healthcare, agriculture, bio-energy, environmental protection, and related fields.
“We are deeply honored that BGI has selected Illumina as its partner for sequencing technology. Our company is strongly committed to helping the Institute achieve its ambitious vision of providing sequencing resources to public and private entities throughout the world,” said Matt Posard, vice president of Global Sales at Illumina. “Illumina is thrilled that BGI selected our recently launched HiSeq 2000 sequencer to enable their vision.”
Installations of HiSeq 2000 systems will begin in the first quarter and continue over the subsequent three quarters. Revenue related to the sale of these instruments is expected to be recognized over the next three years.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.